The United States Food and Drugs Administration – FDA has formally awarded the approval to Thrive Nicotine Polacrilex Gum – the smoking cessation drug developed by Parsippany, NJ based pharmaceutical giants called Novartis Consumer Health. Thrieve is the nicotine based mint flavored gum designed to replace nicotine for the smoker.

Smoking has been proved culprit of causing various cancers and cardiovascular diseases and other disorders both to the smokers as well as their family members. Nicotine addiction is really very tough to get rid of and even if the smoker is willing to give it up, he cannot do so easily. Novartis has now made it possible. The company has developed one smoking cessation gum called Thrive.

It is available in 2mg and 4mg doses and is powerful enough to help smokers quit smoking just within 12 weeks only. According to Novartis, Thrive simply doubles the smoker’s chances of quitting smoking.

As planned, Thrive is likely to go on sale by late 2007 as officially revealed by Novartis and the company has will sell Thrive packages along with user’s guide and an audio CD. The company is also likely to have a toll-free counseling line for helping the intended smokers in their attempt to quit smoking.

Thrieve Nicotine Polacrilex Gum is designed to deliver low levels of nicotine to the blood stream to help diminish the smoking desire and other withdrawal symptoms that are accompanied by the smoking cessation. The company has set the lower dose of 2mg especially for those smokers who smoke less than 25 cigarettes every day and the 4mg dose for the smokers who smoke more than 25 cigarettes per day.